CURRICULUM VITAE
`
`
`
`
`
`
`
`
`
`
`
`
`David Leslie Fogelson
`
`2730 Wilshire Blvd., Suite 325
`Santa Monica, California 90403
`Telephone: (310) 828-5015
`Fax: (310) 829-3877
`E-mail: dfogelso@ucla.edu
`Internet: www.davidfogelson.com
`
`
`Name:
`
`Address:
`
`
`
`
`
`
`
`
`
`
`
`Title:
`
`Clinical Professor, University of California at Los Angeles
`Department of Psychiatry and Biobehavioral Sciences
`
`Los Angeles, California
`
`
`Place of Birth:
`
`Education:
`University of California at Santa Cruz, honors in Biology
`
`1972 B.A.
`
`1977 M.D. Harvard Medical School
`
`Postdoctoral Training:
`
`
`Internship and Residencies:
`
`1977-1978
`Intern in Medicine, The Faulkner Hospital, Boston, MA
`
`1978-1979
`
`Resident in Psychiatry, Tufts University, Court Street
`Veterans Administration Outpatient Clinic, Boston, MA
`
`
`
`
`
`
`1979-1981
`
`
`
`1981-1982
`
`Resident in Psychiatry, The Neuropsychiatric Institute,
`University of California at Los Angeles
`
`Fellow in Psychopharmacology, McLean Hospital,
`Belmont, Massachusetts, a division of Harvard Medical
`School
`
`
`Licenses and Certification:
`
`1977
`
`Massachusetts License Registration No. 43088
`
`
`1977
`
`
`
`
`
`
`Diplomate of the National Board of Medical Examiners,
`No. 179116
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 001
`
`

`
`2
`
`Curriculum Vitae
`David Leslie Fogelson
`Postdoctoral Training:
`
`Licenses and Certification
`1979
`
`California License registration No. G039149
`
`1984
`
`
`2008
`
`
`
`
`
`
`
`
`
`
`Diplomate American Board of Psychiatry and Neurology
`No. 25840
`
`Suboxone Certification
`
`Psychiatric Staff Member, Boston State Hospital, Boston, MA
`
`Psychiatric Staff Member, Olive View Hospital, Los Angeles, CA
`
`Psychiatric Staff Member, McLean Hospital, Belmont, MA
`
`
`
`
`
`Hospital Appointments:
`
`
`1979-1979 Medical Staff Member, Braintree Hospital, Braintree, MA
`
`1978-1979
`
`1979-1981
`
`1981-1982
`
`1982-1984 Medical Staff Member, Encino Hospital, Encino, CA
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1982-1985
`
`1982-1985
`
`
`
`1986-1993
`
`
`1987-1993
`
`1981-2009
`
`
`
`Psychiatric Staff Member, Van Nuys Hospital, Van Nuys, CA
`
`Psychiatric Staff Member, Woodview Calabasas Hospital,
`Calabasas, CA
`
`Psychiatric Staff Member, Westwood Hospital, Westwood, CA
`
`Psychiatric Staff Member, St. John’s Hospital, Santa Monica, CA
`
`Psychiatric Staff Member, UCLA Neuropsychiatric Hospital,
`Westwood, CA
`
`
`
`Awards and Honors:
`
`
`1972
`
`
`1987-1991 Member, Board of Directors, Obsessive Compulsive Foundation
`
`1992
`
` 1996-present Elected by his peers for inclusion in Best Doctors in America®
`
`
`
`
`
`
`
`
`
`
`
`
`Graduated with Honors in Biology from the University of
`California at Santa Cruz
`
`Distinguished Fellow American Psychiatric Association
`
`
`
`2
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 002
`
`

`
`3
`
`Curriculum Vitae
`David Leslie Fogelson
`
`Awards and Honors:
`
`1995
`
`Outstanding Junior Clinical Faculty Teaching Award UCLA
`Neuropsychiatric Institute and Hospital Residency Program
`
`
`Member, Scientific Advisory Board, Obsessive Compulsive
`
`1996
` Foundation of California
`
`
`Major Committee Assignments:
`
`
`1980-1981
`
`Secretary, Committee on Competency in Psychiatric Residency
`Training, Neuropsychiatric Institute, University of California at
`Los Angeles
`
`1982-1984 Member, Adult Psychiatric Committee, Woodview Calabasas
`
`
`Hospital, Calabasas, CA
`
`1982-1983
`
`
`
`Chairman, Adult Patient Care Evaluation Committee,
`Neuropsychiatric Institute, UCLA, Los Angeles, CA
`
`
`
`1982-1987 Member, Specialty Clinics Committee, Neuropsychiatric Institute,
`
`
`UCLA, Los Angeles, CA
`
`1982-1987
`
`Chairman, Clinical Care Utilization Committee, Neuropsychiatric
`Institute, UCLA, Los Angeles, CA
`
`1983-1985 Member, Medical Records Committee, Neuropsychiatric Institute,
`
`
`UCLA, Los Angeles, CA
`
`1984-1986
`
`
`
`Chairman, Pharmacy Committee, Woodview Calabasas Hospital,
`Calabasas, CA
`
`1990-1991
`
`
`
`Chairman, Hospital Psychiatry Committee, Southern California
`Psychiatric Society
`
`1991-1998 Member, Scientific Program Committee, Southern California
`2011-
`Psychiatric Society
`
`1994-1996
`
`
`
`Chairman, Health Care Reform Committee, Southern
`California Psychiatric Society
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 003
`
`

`
`Curriculum Vitae
`David Leslie Fogelson
`Major Committee Assignments:
`
`
`4
`
`1995-1999 Member, APA Practice Research Network Scientific Advisory
`Committee
`
`Elected Offices:
`2009-2012
`
`2013-2014
`
`Southern California Psychiatric Society, Representative
`
`Southern California Psychiatric Society, President Elect
`
`
`Major Research Interests:
`
`
`1. The clinical genetics and pathophysiology of Schizophrenia and Schizophrenia
`Spectrum Disorders; past medical director of a study of two hundred
`schizophrenic patients and their first degree relatives as part of a large
`collaborative research effort.
`
`
`2. Psychopharmacologic treatment of mood, anxiety and schizophrenic disorders.
`
`
`
`
`
`
`
`
`
`
`
`Teaching Experience:
`
`1977-1978
`
`Supervised clinical work in medicine of Tufts University medical
`students at Faulkner Hospital
`
`1979-1981 Organized Psychopharmacology Seminars for Department of
`
`
`Medicine, Wadsworth Hospital, Los Angeles, CA
`
`4
`
`
`Memberships in Professional Societies:
`
`
`1978-1993 American Association for the Advancement of Science
`
`1979
`
`1981
`
`1992-1995 West Coast College of Biological Psychiatry
`
`1992-1995
`
`
`
`
`
`American Psychiatric Association
`
`American Medical Association
`
`The American Academy of Clinical Psychiatrists
`
`2007-2012
`
`Schizophrenia International Research Society
`
`
`
`
`
`
`
`
`
`
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 004
`
`

`
`Curriculum Vitae
`David Leslie Fogelson
`1979-1981
`Supervised clinical work in inpatient psychiatry of UCLA medical
`students and psychiatry residents, Neuropsychiatric Institute,
`UCLA, Los Angeles, CA
`
`5
`
`
`
`1982-Present Supervised and lectured psychiatry residents, psychology interns,
`and medical students, in the outpatient department of the
`Neuropsychiatric Institute, UCLA, Los Angeles, CA
`
`1983-Present Numerous public speaking engagements at hospitals, universities
`and clinics on various topics in psychopharmacology and the
`pathophysiology of schizophrenia.
`
`
`1983-2012
`
`International speaker for Pfizer and Bristol-Myers-Squibb;
`National speaker for Ciba-Geigy, Pfizer, Searle, Lilly, Glaxo-
`Burroughs-Wellcome, Bristol-Myers Squibb, Wyeth and Abbott
`Laboratories; regional speaker for Pfizer, Dista, Sandoz
`Pharmaceuticals, Searle, UpJohn, Bristol-Myers-Squibb, and Mead
`Johnson; local speaker for Organon, Astra-Zeneca, and Parke-
`Davis
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`1984-1995
`
`
`
`1985
`
`
`
`
`
`Coordinate and help run anxiety and mood disorders seminars
`for UCLA psychiatry residents and psychology interns.
`
`Chaired an Anxiety Disorders Symposium sponsored by Wyeth
`Laboratories
`
`1995-2010
`
`
`
`Present Advanced Psychopharmacology lectures to UCLA
`Psychiatry Residents
`
`1996-Present Chair a journal club for UCLA psychiatry faculty
`
`Psychiatrist in Charge, Bowditch Hall Clinical Research Unit,
`McLean Hospital, Belmont, MA
`
`
`Principal Clinical and Hospital Service Responsibilities:
`
`
`1981-1982
`
`
`
`
`
`
`
`
`
`Principal Clinical and Hospital Service Responsibilities:
`
`
`1982-1987 Assistant Director, UCLA Outpatient Psychiatry Department,
`
`
`Los Angeles, CA
`
`1982-1983 Assistant Director, UCLA Affective Disorders Clinic, Los
`Angeles,CA
`
`5
`
`
`
`
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 005
`
`

`
`Curriculum Vitae
`David Leslie Fogelson
`Principal Clinical and Hospital Service Responsibilities:
`
`
`6
`
`1983-1987 Director, Outpatient Psychopharmacology, Neuropsychiatric
`
`
`Institute, UCLA, Los Angeles, CA
`
`1984-1987 Director, Anxiety Disorder Treatment Program, Neuropsychiatric
`
`
`Institute, UCLA, Los Angeles, CA
`
`1984-2011 Medical Director for the UCLA Family Study of Schizophrenia
`
`1988-1992 Director, Intensive Care Unit, Westwood Hospital, Los Angeles,
`
`
`CA
`
`1988-2003
`
`
`
`President, Pacific Psychopharmacology Research Institute,
`Santa Monica, CA
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Media Experience:
`
`
`1982-Present Numerous radio and television interviews
`
`
`
`
`
`
`
`
`
`
`
`
`1986
`
`
`1986
`
`
`1987
`
`1988
`
`
`2000
`
`Co-wrote and moderated two Art Ulene productions for ABC:
`“Panic Disorder” and “Obsessive-Compulsive Disorder”.
`
`Wrote and moderated two C.M.E. network video productions:
`“The Pharmacokinetics of Benzodiazepines” and “Panic Disorder”
`
`CME Network: “Obsessive Compulsive Disorder”
`
`Interview on KTWV radio about the holiday blues and
`seasonal depression
`
`
`
`Web-casting, lectures from the UCLA Web studio on
`psychopharmacology
`
`
`Editor for:
`
`Efocus, the continuing medical education electronic journal of the APA (2012-
`present)
`
`
`Reviewer for:
`
`
`American Journal of Psychiatry (1982-present)
`
`Journal of Clinical Psychopharmacology (1988-present)
`
`
`
`6
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 006
`
`

`
`
`
`
`
`American Psychiatric Association “Practical Guidelines” Series (Fall 1991)
`
`Consultant for American Psychiatric Association Practice Guidelines for Eating
`Disorders, American Journal of Psychiatry, Vol. 150, No. 2, Feb. 1993, p. 207-
`288
`
`Consultant for American Psychiatric Association Practice Guidelines for the
`Treatment of Patients With Bipolar Disorder, American Journal of Psychiatry
`151:12, Dec. 1994 Supplement
`
`Schizophrenia Research (2007-present)
`
`Consultant for American Psychiatric Association Practice Guidelines for the
`Treatment of Patients With Bipolar Disorder, American Journal of Psychiatry;
`2009 Edition.
`
`eFOCUS, the continuing electronic medical education journal for the American
`Psychiatric Association
`
`
`
`7
`
`Curriculum Vitae
`David Leslie Fogelson
`
`
`
`
`Reviewer for:
`
`Brain and Behavior (2014-present)
`
`Journal of Neuropsychiatry and Clinical Neurosciences (1996-present)
`
`
`Biography:
`
`Journals:
`
`Fogelson, D.L.; Marder, S.R.; Van Putten, T.: “Dialysis for Schizophrenia:
`Review of Clinical Trials and Implications for Further Research”, Am J
`Psychiatry, 137:605-607, 1980.
`
`
`
`
`
`
`
`Fogelson, D.L.; Cohen, B.M.; Pope, Jr., H.G.: “DSM III Schizophreniform
`Disorder”, Am J Psychiatry, 139:1281-1285, 1982.
`
`Arana, G.W.; Berreira, P.J.; Cohen, B.M.; Lipinski, J.F.; Fogelson, D.L.: “The
`Dexamethasone Suppression Test in Psychotic Disorders”, Am J Psychiatry,
`140:1521-1523, 1983.
`
`Nuechterlein, K.H.; Snyder, K.; Dawson, M.; Rappe, S.; Gitlin, M.; Fogelson,
`D.L.: “Expressed Emotion, Fixed Dose Fluphenazine Treatment, and Relapse in
`Recent-Onset Schizophrenia”, Psychopharmacology Bulletin, 22(3):633-639,
`1986.
`
`7
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 007
`
`

`
`8
`
`Curriculum Vitae
`David Leslie Fogelson
`
`
`
`
`Biography:
`
`Journals:
`
`Gitlin, M.J.; Midha, K.K.; Fogelson, D.L.; Nuechterlein, K.H.: “Persistence of
`Fluphenazine in Plasma After Decanoate Withdrawal”, J. Clin Psychopharmacol,
`8(1):53-56, 1988.
`
`Fogelson, D.L.; Bystritsky, A.; Sussman, N.: “Inter-Relationships Between Major
`Depression and the Anxiety Disorders: Clinical Relevance”, Psychiatric Annals,
`18(3):158-167, 1988.
`
`Nuechterlein, K.H.; Dawson, M.; Ventura, J.; Fogelson, D.L.; Gitlin, M.; Mintz,
`J.: “Testing Vulnerability Models: Stability of Potential Vulnerability Indicators
`Across Clinical State”, In H. Haefner and W.F. Gattaz (Eds.) Search for the
`Causes of Schizophrenia, Vol. 2. Springer-Verlag Berlin Heidelberg, 1990.
`
`Clomipramine Study Group (Fogelson, D.L., member of group): “Clomipramine
`in the Treatment of Patients With Obsessive-Compulsive Disorder”, Arch Gen
`Psychiatry, 48(8):730-738, 1991.
`
`Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Subotnik, K.; Talovic, S.A.:
`“Interrater Reliability of the Structured Clinical Interview for DSM-III-R, Axis
`II: Schizophrenia Spectrum and Affective Spectrum Disorders”, Psych Research,
`39:55-63, 1991.
`
`Fogelson, D.L.; Bystritsky, A.: “Imipramine in the Treatment of Obsessive
`Compulsive Disorder With and Without Major Depression”, Annals of Clin.
`Psychiatry, 3(3):233-237, 1991.
`
`Fogelson, D.L.; Jacobson, S.; Sternbach, H.: “A Retrospective Study of Valproate
`in Private Practice”, Annals of Clin. Psychiatry, 3(4):315-320, 1991.
`
`Fogelson, D.L., Epitome: Obsessive Compulsive Disorder, The Western Journal
`of Medicine, 155(5):522, 1991.
`
`Goldstein, M.J.; Talovic, S.A.; Nuechterlein, K.H.; Fogelson, D.L.; Subotnik,
`K.L.; Asarnow, R.F.: “Family Interaction Versus Individual Psychopathology:
`Do They Indicate the Same Processes in the Families of Schizophrenics?”, British
`Journal of Psychiatry, Suppl., 161(18):97-102, 1992.
`
`
`
`
`
`
`
`8
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 008
`
`

`
`Curriculum Vitae
`David Leslie Fogelson
`
`9
`
`
`
`Biography:
`
`Journals:
`
`
`
`
`
`
`
`
`
`Bystritsky, A.; Fogelson, D.L.; Doctor, R.; Yager, J.: “Symptom Differences
`Among Anxiety Patients in Clinics with Differing Treatment Orientations: A
`Pilot Investigation”, J. Psychotherapy, 2(2), Spring 1993.
`
`Fogelson, D.L.; Bystritsky, A.; Pasnau, R.: “Bupropion in the Treatment of
`Bipolar Disorders: The Same Old Story?”, J. Clinical Psychiatry, 53:443-446,
`1992.
`
`Subotnik, K.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Goldstein,
`M.J.; Talovic, S.A.: “Depressive Symptoms in the Early Course of
`Schizophrenia: Relationship to Familial Psychiatric Illness”, Am J Psych,
`151(11):1551-1556, 1997.
`
`Gitlin, M.; Nuechterlein, K.H.; Mintz, J.; Fogelson, D.L.; Bartzokis, G.;
`Aravagiri, M.: “Fluphenazine Levels During Maintenance Treatment of Recent
`Onset Schizophrenia: Relation to Side Effects, Psychosocial Function and
`Depression”, Psychopharmacology 148:350-354, 2000.
`
`Fogelson, D.L., Nuechterlein, K.H.H., Asarnow, R.F.F., Payne, D.L., Subotnik,
`K.L, Giannini, C.: “The Factor Structure of Schizophrenia Spectrum Signs and
`Symptoms in First-Degree Relatives of Schizophrenic Patients from the UCLA
`Family Members Study”, Psychiatry Research 87:137-146, 1999.
`
`Asarnow, R.F., Nuechterlein, K.H., Fogelson, D.L., Subotnik, K.L., Payne, D.L.,
`Russell, AT., Asamen, J., Kuppinger, H., Kendler, K.S., Schizophrenia and
`Schizophrenia Spectrum Personality Disorders in the First-Degree Relatives of
`Children with Schizophrenia: The UCLA Family Members Study, Arch of
`General Psychiatry, 58:581-588, 2001.
`
`Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL,
`Bartzokis G, Aravagiri M, Clinical outcome following neuroleptic
`discontinuation in patients with remitted recent-onset schizophrenia. Am J
`Psychiatry, 158(11):1835-42, 2001.
`
`Asarnow R, Nuechterlein K, Asamen J, Fogelson DL, Subotnik KL, Zaucha K,
`Guthrie D: Neurocognitive functioning and schizophrenia spectrum disorders
`can be independent expressions of familial liability for schizophrenia in
`community control children: the UCLA family study, Schizophrenia Research.
`54:111-120, 2002.
`
`9
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 009
`
`

`
`Curriculum Vitae
`David Leslie Fogelson
`
`10
`
`
`
`Biography:
`Journals:
`
`Neuchterlein KH, Asarnow RF, Subotnik KL, Fogelson DL, Payne DL, Kendler
`KS, Neale MC, Jacobson KC, Mintz J: The Structure of Schizotypy:
`Relationships Between Neurocognitive and Personality Disorder Features in
`Relatives of Schizophrenic Patients in the UCLA Family Study. Schizophrenia
`Research, 54:121-130, 2002.
`Asarnow RF, Nuechterlein KH, Subotnik KL, Fogelson DL, Torquato RD, Payne
`DL, Asamen J, Mintz J, Guthrie D: Neurocognitive Impairments in Non-psychotic
`Parents of Children with Schizophrenia and Attention Deficit Disorder: The
`UCLA Family Study. Arch of General Psychiatry, 59:1053-1060, 2002.
`
`Fogelson DL, Nuechterlein KH, Asarnow RF, Payne DL, Subotnik KL.
`Validity of the family history method for diagnosing schizophrenia,
`schizophrenia-related psychoses, and schizophrenia-spectrum personality
`disorders in first-degree relatives of schizophrenia probands.
`Schizophr Res, 68:309-17, 2004.
`
`Subotnik KL, Asarnow RF, Nuechterlein KH, Fogelson DL, Thorpe TI, Payne
`DL, Giannini CA, Kuppinger HE, Torquato RD, Mintz J, Hwang SS, Gottesman
`II. MMPI vulnerability indicators for schizophrenia and attention deficit disorder:
`UCLA family study of biological parents of offspring with childhood-onset
`schizophrenia or ADHD. Behav Genet., 35(2):159-75, 2005.
`
`Fogelson DL, Nuechterlein KH, Asarnow RA, Payne DL, Subotnik KL, Jacobson
`KC, Neale MC, Kendler KS: Avoidant personality disorder is a separable
`schizophrenia-spectrum personality disorder even when controlling for the
`presence of paranoid and schizotypal personality disorders The UCLA family
`study. Schizophr Res, 91:192-9, 2007.
`Fogelson DL, Asarnow RA, Sugar CA, Subotnik KL, Jacobson KC, Neale MC,
`Kendler KS, Kuppinger H, Nuechterlein KH. Avoidant personality disorder
`symptoms in first-degree relatives of schizophrenia patients predict performance
`on neurocognitive measures: The UCLA family study. Schizophr Res, 2010 Jan
`4, Ahead of Print.
`
`
`Biography:
`Letters:
`Fogelson, D.L.: “Using Carbamazepine Effectively”, Am J Psychiatry, 141:1130,
`1984.
`
`
`
`
`10
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 010
`
`

`
`11
`
`Curriculum Vitae
`David Leslie Fogelson
`
`Biography:
`Letters:
`
`Fogelson, D.L.: “Lorazepam and Oxazepam in the Treatment of Panic Disorder”.
`J. Clin Psychopharmacology, 8(2):150-151,1988.
`
`
`
`
`
`
`
`
`Fogelson, D.L.: “Weight Gain During Fluoxetine Treatment”, J. Clin
`Psychopharmacology, 11(3):220, 1991.
`
`Fogelson, D.L.: “Nefazodone and/or Sodium Tetradecyl Sulfate Associated
`Leukopenia, Fever and Shaking Chills in a Patient with Premenstrual Dysphoric
`Disorder”, J. Clin Psychopharmacology, 17(3):222-223, 1997.
`
`Fogelson, D.L.; Sternbach, H.: “Lamotrigine Treatment of Refractory Bipolar
`Disorder”, J. Clin Psychiatry, 58(6):271-273, 1997.
`
`Fogelson, D.L.: “Fenfluramine and the Cytochrome”, P450 System. Am. J.
`Psychiatry, 154(3):436-437, 1997.
`
`
`
`
`
`Fogelson, D.L.; Sternbach, H.; Payne, D.: “A Naturalistic Pilot Study Comparing
`Haloperidol, Clozapine, Sertindole, and Risperidone in Partially Responsive
`Chronic Schizophrenia or Schizoaffective Disorder”, J Clin Psychopharmacology,
`17(6):492-494, 1997.
`
`Biography:
`Abstracts:
`
`
`
`Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Goldstein,
`M.J.; Mintz, J.: “Depressive Symptoms in Recent-Onset Schizophrenia Patients
`Are Associated With a Family History of Depression”. Presented at theAmerican
`Psychiatric Association annual meeting. May 21, 1997, San Diego, CA.
`
`
`
`
`
`Nuechterlein, K.H.; Subotnik, K.L.; Asarnow, R.F.; Gottesman, I.; Fogelson,
`D.L.; Payne, D.L.; Torquato, R.D.: “MMPI Profiles of First-Degree Relatives of
`Recent-Onset Schizophrenia Probands”. Presented at the International Congress
`on Schizophrenia Research 1997.
`
`Asarnow, R.F.; Nuechterlein, K.H.; Torquato, R.D.; Subotnik, K.L.;
`Fogelson,D.L.: “Cognitive/Neuropsychological Abnormalities in the Parents of
`Children with a Schizophrenic Disorder”. Presented at the International Congress
`on Schizophrenia Research 1997.
`
`11
`
`
`
`
`
`
`
`
`
`
`
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 011
`
`

`
`12
`
`Curriculum Vitae
`David Leslie Fogelson
`
`Biography:
`Abstracts:
`
`
`Subotnik, K.L.; Asarnow, R.F.; Nuechterlein, K.H.; Payne, D.L.; Fogelson, D.L.;
`Gottesman, I.I.: “MMPI Differences Among First-Degree Relatives of Probands
`with Childhood-Onset Schizophrenia, Attention Deficit Disorder, and Normal
`Control Children”. Presented at the International Congress on Schizophrenia
`Research 1997.
`
`Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Payne, D.L.; Subotnik, K.L.;
`Giannini, C.: “The Factor Structure of Schizophrenia Spectrum signs and Family
`
`Members Study”. Presented at the International Congress on Schizophrenia
`Research 1997.
`
`Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Goldstein, M.J., Fogelson,
`D.L.; Richard D. Torquato: “Communication Deviance is Associated with
`Putative Genetic Vulnerability Indicators in Relatives of Schizophrenia Patients”.
`Presented at the International Congress on Schizophrenia Research, 1999.
`
`Fogelson, D.L.; Torquato, R.D.; Asarnow, R.F.; Subotnik, K.L.: “Are Categorical
`or Dimensional Approaches to Personality Disorders Better for Discriminating the
`Biological Parents of Probands with Childhood-Onset Schizophrenia Versus
`ADD”. Presented at the International Congress on Schizophrenia Research, 1999.
`
`Nuechterlein, K.H.; Subotnik, K.L.; Gitlin, M.; Dawson, M.E.; Ventura, J.;
`Snyder, K.S.; Fogelson, D.L.; Shaw, S.; Mintz, J.: “Neurocognitive and
`Environmental Contributors to Work Recovery After Initial Onset of
`Schizophrenia: Answers from Path Analyses”. Presented at the International
`Congress on Schizophrenia Research, 1999.
`
`Payne, D.L.; Kuppinger, H.E.; Asarnow, R.F.; Subotnik, K.L.; Fogelson, D.L.;
`Nuechterlein, K.H.: “Examination of Wisconsin Psychosis-Proneness Scales as
`an Indication of Familial Vulnerability to Schizophrenia”. Presented at the
`International Congress on Schizophrenia Research, 1999.
`
`Asarnow, R.F.; Nuechterlein, K.H.; Fogelson, D.L.; Subotnik, K.L.; Torquato,
`R.D.; Payne, D.L.; Kuppinger, H.E.: “Defining the Boundaries of the
`Schizophrenia Phenotype: The UCLA Family Study”. Presented at the
`International Congress on Schizophrenia Research, 1999.
`
`12
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 012
`
`

`
`Curriculum Vitae
`David Leslie Fogelson
`
`13
`
`
`
`
`
`Biography:
`Abstracts:
`
`
`Subotnik, K.L.; Asarnow, R.F.; Fogelson, D.L.; Gottesman, I.I.; Thorpe, T.;
`Payne, D.L.; Giannini, C.; Torquato, R.; Kuppinger, H.E.; Nuechterlein, K.H.:
`“MMPI Vulnerability Indicators for Schizophrenia: Findings from the UCLA
`Family Study Examining Biological Parents of Children with Schizophrenia or
`Attention Deficit Disorder and Parents of Community Controls”. Presented at the
`2nd International Conference on Early Psychosis March 31, 2000. New York.
`
`
`Biography:
`Abstracts:
`
`
`
`Asarnow, R.F.; Nuechterlein, K.H.; Subotnik, K.L.; Fogelson, D.L.; Torquato,
`R.D.; Payne, D.L.; Guthrie, D.: “Specificity of Neurocognitive Impairments in
`Parents of Probands with Childhood Onset of Schizophrenia”. Presented at the
`International Congress on Schizophrenia Research, 2001.
`
`Subotnik, K.L.; Nuechterlein, K.H.; Gitlin, M.; Siegel, B.; Bartzokis, G.;
`Fogelson, D.L.; Ventura, J.: “First Episode Patients Treated With Risperidone
`Show Better Neurocognitive and Functional Outcome Than Patients Treated with
`Fluphenazine Decanoate”. Presented at the International Congress on
`Schizophrenia Research, 2001.
`
`Nuechterlein, K.H.; Asarnow, R.F.; Jacobson, K.; Subotnik, K.L.; Neale, M.;
`Fogelson, D.L.; Kendler, K.: “Neurocognitive Vulnerability Factors in First-
`Degree Relatives of Schizophrenic Probands Show Accelerated Aging Effects”.
`Presented at the International Congress on Schizophrenia Research, 2001.
`
`Yee, C.M.; Nuechterlein, K.H.; Morris, S.E.; Gitlin, M.J.; Fogelson, D.L.;
`Bartzokis, G.; Subotnik, K.L.: “Rates of Smoking in Recent-onset Schizophrenia
`Patients Receiving Traditional Versus Atypical Antipsychotic Medications”.
`Presented at the International Congress on Schizophrenia Research, 2001.
`
`Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.F.; Payne, D.; Subotnik, K.L.;
`Kuppinger, H.: “Validity of the Family History Method for Diagnosing
`Schizophrenia and Schizophrenia related Psychoses in First-Degree Relatives of
`Schizophrenic Probands”. Presented at the International Congress on
`Schizophrenia Research, 2001.
`
`
`
`13
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 013
`
`

`
`14
`
`Curriculum Vitae
`David Leslie Fogelson
`
`Biography:
`Abstracts:
`
`
`Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.A.; Subotnik, K.L.; Payne, D.L.;
`Jacobson, K.C.; Neale, M.C.; Kendler, K.S.: “Avoidant Personality Disorder
`Increases the Detection of First Degree Relatives Affected by a Schizophrenia
`Spectrum Diagnosis”. Accepted to the International Congress on Schizophrenia
`Research, 2003.
`
`
`
`Subotnik, K.L.; Nuechterlein, K.H.; Asarnow, R.F.; Fogelson, D.L.; Payne, D.L.;
`Ventura, J.; Kendler, K.S.:”Relationship between positive and negative symptoms
`of schizophrenia and dimensions of personality pathology in biological parents”.
`Accepted to the International Congress on Schizophrenia Research, 2003.
`
`Fogelson, D.L.; Nuechterlein, K.H.; Asarnow, R.A.; Subotnik, K.L.; Payne, D.L.;
`Jacobson, K.C.; Neale, M.C.; Kendler, K.S.; Sugar, C.: “Avoidant Personality
`Disorder Symptoms in First-Degree Relatives of Schizophrenics Predict
`Performance on Neurocognitive Measures The UCLA Family Study”. Presented
`at the International Congress on Schizoprhenia Research, 2009
`
`
`Biography:
`Chapters:
`
`
`
`
`
`
`
`
`
`
`Biography:
`Research:
`
`
`Clinical research trials run at the Pacific Psychopharmacology Research Institute:
`
`Co-author of the Psychiatric Knowledge and Skills Assessment Program -
`Anxiety Disorders Section, American Psychiatric Association
`
`Lenzenweger, M.F. & Dworkin, R.H. (Eds.). (in press). The Pathogenesis of
`Schizophrenia: An Experimental Psychopathology Perspective. Washington,
`DC:American Psychological Association. Chapter on: Neurocognitive
`VulnerabilityFactors for Schizophrenia: Convergence Across Genetic Risk
`Studies and Longitudinal Trait/State Studies. Nuechterlein, K.H., Asarnow, R.F.,
`Subotnik, K.L., Fogelson, D.L., Ventura, J., Torquato, R.D., Dawson, M.E.
`
`Anafranil multicenter trial, 1986-1987, Ciba Geigy, for Obsessive Compulsive
`Disorder, placebo controlled.
`
`
`
`
`
`
`Buspar multicenter trial, 1987-1988, Mead Johnson, for Xanax withdrawal, phase
` IV.
`
`
`
`
`14
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 014
`
`

`
`15
`
`Curriculum Vitae
`David Leslie Fogelson
`
`Tandospirone multicenter trial, 1989-1990, Pfizer, for Panic Disorder, placebo
`
`controlled.
`
`Biography:
`Research:
`
`
`Tandospirone multicenter trial, 1991-1992, Pfizer for Major Depression, placebo
` controlled.
`
`
`
`Ondansetron multicenter trial, 1991, Glaxo, for Generalized Anxiety Disorder,
` placebo controlled.
`
`Anafranil multicenter trial, 1991-1993, Ciba Geigy, for Obsessive Compulsive
`Disorder with Depression.
`
`
`
`
`
`
`Brofaromine multicenter trial, 1992-1993, Ciba Geigy, for Social Phobia, placebo
` controlled.
`
`Fluvoxamine multicenter trial, 1992, Upjohn, for Panic Disorder, placebo
` controlled.
`
`
`Sertindole multicenter trial, 1994, Abbott labs, for Schizophrenia.
`
`Lamictal multicenter trial, 1997, Glaxo-Wellcome labs, for Bipolar Depression
`
`Aripiprazole multicenter trial, 1998, Otsuka, for Schizophrenia
`
`Ziprasidone multicenter trial, 1998-2003, Otsuka, for Schizophrenia
`
`Substance P Antagonist multicenter trial, 1999, Novartis, for Social Phobia.
`11 patients were randomized.
`
`Fluoxetine-Olanzapine multicenter trial, 2000, Eli Lilly for Treatment resistant
`Depression
`
`193 98 203 multicenter trial, 2000, Otsuka for Major Depression
`
`Leviteracetam, multicenter trial, 2003, USB Pharma, Social Phobia
`
`15
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Roxane Labs., Inc.
`Exhibit 1004
`Page 015